General Information
Version
6.6
Revision date
2024-07-02
Product name
ApopTag Plus Fluorescein In Situ Apoptosis
REACH No
This
1.2.1 Relevant identified uses
Biochemical research/analysis
Icons in SDS
Company Information
company name
Merck Pty Ltd
GHS Information
Signal word
Danger
Hazard Codes
Hazard statements (CLP)
H350, H373, H411
Hazard statements
Code
Statements
H350
May cause cancer
Section 2
SECTION 2: Hazards identification
2.1 Classification of the substance or mixture
Carcinogenicity, (Category 1B) H350 May cause cancer Specific target organ toxicity - H373: May cause damage to organs repeated exposure, (Category 2), through prolonged or repeated exposure if Respiratory Tract inhaled. Long-term (chronic) aquatic H411: Toxic to aquatic life with long lasting hazard, (Category 2) effects.
2.2 Label elements
Labelling
Signal word
Danger Danger
Hazard statements
H350 May cause cancer. H373 May cause damage to organs (Respiratory Tract) through prolonged or repeated exposure if inhaled. H411 Toxic to aquatic life with long lasting effects. H350 May cause cancer.
Precautionary statements
P202 Do not handle until all safety precautions have been read and understood. P260 Do not breathe mist or vapors. P273 Avoid release to the environment. P280 Wear protective gloves/ protective clothing/ eye protection/ face protection. P308 + P313 IF exposed or concerned: Get medical advice/ attention. P391 Collect spillage. P202 Do not handle until all safety precautions have been read and understood. P280 Wear protective gloves/ protective clothing/ eye protection/ face protection. P308 + P313 IF exposed or concerned: Get medical advice/ attention.
Supplemental label elements
none Reduced Labeling (<= 125 ml) none
Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher
ECOLOGICAL INFORMATION
The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.
TOXICOLOGICAL INFORMATION
The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.
